Jae Lee, MD
Hematology & Oncology · Eugene, ORNPI 1154307080
Payments from drug & device makers
What this record shows
This record is dominated by education: $86 of the $104 with a category attached, or 83.0%. E.r. Squibb & Sons, L.L.C. accounts for 71.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $74 and has fallen 76.2% since, to $18 in 2022. That places this record below the midpoint for hematology & oncology clinicians in OR, where the typical reported total is $847.
Across 6 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$74
- Baxter Healthcare$18
- Gilead$12
Across 8 payments — averaging $1178.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$9K
- E.r. Squibb & Sons, L.L.C.$476
- AstraZeneca$143
What the payments were for
- Food & beverage$1817%
- Education$8683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Baxter Healthcare | 1 | $18 |
| Gilead | 1 | $12 |
How this compares
$104 in reported general payments places this provider in the 15th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 25 | $435,192 |
| BrukinsaZanubrutinib | 25 | $317,539 |
| CalquenceAcalabrutinib Maleate | 21 | $304,537 |
| Lenalidomide | 13 | $192,085 |
| Anastrozole | 81 | $1,507 |
| Tamoxifen Citrate | 25 | $788 |
| Oxycodone Hcl | 34 | $657 |
| Hydroxyurea | 25 | $487 |
| Prochlorperazine Maleate | 18 | $433 |
| Acyclovir | 19 | $319 |
| Prednisone | 44 | $271 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $266 |
| Levothyroxine Sodium | 14 | $266 |
| Letrozole | 17 | $225 |
| Ondansetron Hcl | 14 | $128 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Eugene
- Christopher YasenchakEugene$102K
- Luke FletcherEugene$44K
- James ButrynskiEugene$1K
- Matthew LonerganEugene$941
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Elie TraerPortland$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.